Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-29
2008-12-30
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S081000
Reexamination Certificate
active
07470704
ABSTRACT:
The compounds of formula Iin which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.
REFERENCES:
patent: 6008215 (1999-12-01), Flockerzi
patent: 6143759 (2000-11-01), Flockerzi
patent: 6306869 (2001-10-01), Flockerzi
patent: 6436952 (2002-08-01), Flockerzi
patent: 2004/0097537 (2004-05-01), Flockerzi
patent: 98/21208 (1998-05-01), None
patent: 98/40382 (1998-09-01), None
patent: 99/57118 (1999-11-01), None
patent: 00/12501 (2000-03-01), None
patent: 02/066476 (2002-08-01), None
patent: 2004/018465 (2004-03-01), None
Montana et al., “Phosphodiesterase 4 inhibitors”,Annual Reports in Medicinal Chemistry, (2001), 36, chapter 5.
Souness et al. “Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors”,Immunopharmacology, 47 (2000), pp. 127-162.
Flockerzi Dieter
Hummel Rolf-Peter
Reutter Felix
Desai Rita J
Goldberg Joshua B.
McGee Sheldon M.
Nath Law Group
Nycomed GmbH
LandOfFree
Benzonaphthyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzonaphthyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzonaphthyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028665